The drug would then be offered to those with a BMI of more than 40 plus two weight-related health problems and then to people with a BMI score of more than 40 plus one weight-related health problem.

Our round-up of financings in the biotech sector this week is led by BioAge Lab's filing of an initial public offering (IPO), with a placeholder target of $100 million, plus sizeable private ...

Wes Streeting’s new plan to give obese patients weight loss injections so they can return to work was torn apart by a doctor ...

Because of the very large number of people who could potentially benefit, Nice accepts that a phased roll out is required Dr ...

Dubbed the “King Kong” of weight loss jabs, Mounjaro, the brand name for tirzepatide ... for long-term blood sugar and appetite control. Plus, if the drug is stopped people put fat back ...

Eli Lilly's weight-loss drug is no longer on the Food and Drug Administration's drug shortage list. Compounding pharmacies say this will limit patient access.

Officials say it's a good sign for the industry that tirzepatide, sold under the brand ... Get a brief on the top business stories of the week, plus CEO interviews, market updates, tech and ...

Maggie O’Neill is a health writer and reporter based in New York who specializes in covering medical research and emerging wellness trends, with a focus on cancer and addiction. Prior to her ...

A much younger treatment from Eli Lilly called tirzepatide earned its first FDA ... still-experimental amylin analog called cagrilintide plus semaglutide. The Redefine-1 study randomized 3,400 ...

Discover why Sagimet Biosciences' Denifanstat is a top contender in treating MASH, with FDA designation and strong financials ...